For research use only. Not for therapeutic Use.
Empagliflozin（Cat No.:I005188）, a type 2 sodium-glucose cotransporter (SGLT-2, sodium-dependentglucosecotransporterChemicalbook2) inhibitor jointly developed by Boehringer Ingelheim and Eli Lilly and Company. SGLT-2 inhibitor is a new type of hypoglycemic drug, mainly by inhibiting the expression of SGLT-2, reducing the reabsorption of glucose by the kidneys, increasing the excretion of glucose in the urine, thereby reducing plasma glucose levels, and its hypoglycemic effect does not depend on in β-cell function and insulin resistance.
| Catalog Number | I005188 |
| CAS Number | 864070-44-0 |
| Synonyms | (2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol |
| Molecular Formula | C₂₃H₂₇ClO₇ |
| Purity | ≥95% |
| Target | SGLT |
| Solubility | DMSO > 125 mg/ml |
| Storage | 2-8°C |
| IC50 | 3.1 nM |
| IUPAC Name | (2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol |
| InChI | InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1 |
| InChIKey | OBWASQILIWPZMG-QZMOQZSNSA-N |
| SMILES | C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl |
| Reference | </br>1:Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin. Sanon VP, Patel S, Sanon S, Rodriguez R, Pham SV, Chilton R.Ther Clin Risk Manag. 2017 May 3;13:603-611. doi: 10.2147/TCRM.S97619. eCollection 2017. Review. PMID: 28496330 Free PMC Article</br>2:The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial. Larsen EL, Cejvanovic V, Kjær LK, Vilsbøll T, Knop FK, Rungby J, Poulsen HE.BMJ Open. 2017 May 9;7(5):e014728. doi: 10.1136/bmjopen-2016-014728. PMID: 28490557 Free Article</br>3:The Sodium-Glucose Co-Transporter 2 Inhibitor, Empagliflozin, Protects against Diabetic Cardiomyopathy by Inhibition of the Endoplasmic Reticulum Stress Pathway. Zhou Y, Wu W.Cell Physiol Biochem. 2017 May 4;41(6):2503-2512. doi: 10.1159/000475942. [Epub ahead of print] PMID: 28472796 Free Article</br>4:Long-Term Efficacy and Safety of Empagliflozin Monotherapy in Drug-Naïve Patients with Type 2 Diabetes in Indian Subgroup: Results from a 76-week Extension Trial of Phase III, Double-Blind, Randomized Study. Gupta S, Shaikh S, Joshi P, Bhure S, Suvarna V.Indian J Endocrinol Metab. 2017 Mar-Apr;21(2):286-292. doi: 10.4103/ijem.IJEM_517_16. PMID: 28459027 Free PMC Article</br>5:Absolute benefits of empagliflozin in type 2 diabetes: a game changer? Kumana CR, Tan KCB, Cheung BMY.Postgrad Med J. 2017 Apr 22. pii: postgradmedj-2016-134741. doi: 10.1136/postgradmedj-2016-134741. [Epub ahead of print] No abstract available. PMID: 28433975 </br>6:Empagliflozin and Kinetics of Renal Glucose Transport in Healthy and Type 2 Diabetic Individuals. Al-Jobori H, Daniele G, Cersosimo E, Triplitt C, Norton L, DeFronzo RA, Abdul-Ghani M.Diabetes. 2017 Apr 20. pii: db170100. doi: 10.2337/db17-0100. [Epub ahead of print] PMID: 28428225 </br>7:Effect of Empagliflozin on Tacrolimus-induced Pancreas Islet Dysfunction and Renal Injury. Jin J, Jin L, Luo K, Lim SW, Chung BH, Yang CW.Am J Transplant. 2017 Apr 19. doi: 10.1111/ajt.14316. [Epub ahead of print] PMID: 28422431 </br>8:Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial. Tanaka A, Shimabukuro M, Okada Y, Taguchi I, Yamaoka-Tojo M, Tomiyama H, Teragawa H, Sugiyama S, Yoshida H, Sato Y, Kawaguchi A, Ikehara Y, Machii N, Maruhashi T, Shima KR, Takamura T, Matsuzawa Y, Kimura K, Sakuma M, Oyama JI, Inoue T, Higashi Y, Ueda S, Node K; EMBLEM Trial Investigators..Cardiovasc Diabetol. 2017 Apr 12;16(1):48. doi: 10.1186/s12933-017-0532-8. PMID: 28403850 Free PMC Article</br>9:Mechanisms linking empagliflozin to cardiovascular and renal protection. Perrone-Filardi P, Avogaro A, Bonora E, Colivicchi F, Fioretto P, Maggioni AP, Sesti G, Ferrannini E.Int J Cardiol. 2017 Mar 23. pii: S0167-5273(17)31358-X. doi: 10.1016/j.ijcard.2017.03.089. [Epub ahead of print] PMID: 28395981 </br>10:Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial? Shi X, Verma S, Yun J, Brand-Arzamendi K, Singh KK, Liu X, Garg A, Quan A, Wen XY.Mol Cell Biochem. 2017 Apr 8. doi: 10.1007/s11010-017-3018-9. [Epub ahead of print] PMID: 28391552 |
